Crinetics | News & Events

PRESS RELEASES

Press Release | November 16, 2020

Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology

Press Release | November 13, 2020

Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for Treatment of Acromegaly

Press Release | November 6, 2020

Third Quarter 2020 Financial Results and Corporate Update

Press Release | October 26, 2020

ACROBAT Edge Study of Paltusotine in Acromegaly Met Endpoint

Press Release | September 21, 2020

Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism

Press Release | September 4, 2020

New Data from Paltusotine and ACTH Antagonist Development Programs- European Congress of Endocrinology

Press Release | September 3, 2020

Crinetics Pharmaceuticals Appoints Rare Disease Executive, Camille L. Bedrosian, M.D., to Board of Directors

Press Release | September 3, 2020

Crinetics Pharmaceuticals to Participate in September Investor Conferences

Press Release | August 7, 2020

Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Press Release | July 8, 2020

FDA Grants Crinetics Pharmaceuticals (CRNX) Orphan Drug Designation - Paltusotine for the Treatment of Acromegaly

19 / 25

Transforming Endocrine Disease Treatment

Be the first to know about the advances we're making in endocrine-rooted care.

Email Signup